(Press-News.org) (WASHINGTON, October 25, 2010) – An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia. While the guideline cautions that ESAs are associated with shorter survival and increased risk of thromboembolism — blood clots — and tumor progression, it also recognizes their major benefit of reducing the need for red blood cell transfusions, which can potentially cause serious infections and adverse reactions in the immune system.
"This updated guideline offers clinicians the latest synthesis of the medical evidence surrounding use of ESAs in patients with cancer, including appropriate cautions where evidence is lacking or where risks may outweigh the use of ESAs," said J. Douglas Rizzo, MD, MS, Co-Chair of the guideline panel and Professor of Medicine at the Medical College of Wisconsin.
Those risks may include thromboembolism or even death, according to new data cited in the guideline, which suggests that physicians avoid the use of ESAs in cancer patients who are not receiving chemotherapy, except for those with myelodysplastic syndrome (MDS). At the same time, the guideline confirms the effectiveness of ESAs in sparing patients the need for transfusions, which can substantially impact quality of life. By recommending that physicians discuss individual risks and benefits of ESAs and blood transfusion with patients prior to therapy, the guideline recognizes the critical role of shared decision-making between the patient and the physician.
In addition to outlining the clotting risks of ESAs, the guideline makes specific recommendations on usage and provides insights into disease progression and patient survival. The guideline also details new thresholds for initiation and modification of ESAs, which are consistent with current FDA labeling.
Originally published in 2002 and last updated in 2007, the guideline was derived from analysis of individual patient data, various medical literature, and systematic reviews of published clinical trials. In developing the update, panel members considered all relevant literature published between January 2007 and January 2010. Additional evidence was considered when it was considered pertinent to each section of the updated guideline.
"These guidelines touch on almost all aspects of the use of ESAs in patients with cancer and MDS, as well as secondary issues, such as the role of iron supplementation," said Samuel Silver, MD, a member of ASH's Committee on Practice and Professor of Internal Medicine at the University of Michigan. "These are issues that confront practicing hematologists and oncologists on a daily basis, and we hope that these evidence-based recommendations will influence practice standards and result in better care for patients."
INFORMATION:
The guideline will be published ahead of print on the websites of Blood (bloodjournal.org), ASH's scientific journal, and ASCO's Journal of Clinical Oncology (jco.org) at 4:00 p.m. on October 25. The guideline will be published in print in Blood on November 18 and in the Journal of Clinical Oncology on November 20.
The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers weekly, available in print and online at www.bloodjournal.org. Follow ASH on Twitter at ASH_hematology.
END
For the first time, scientists have discovered that a poorly understood class of RNA produced in a mammal's cells during a respiratory virus attack may affect the outcome of the infection. Their findings are reported today in mBio, a journal of the American Society for Microbiology.
RNA (ribonucleic acid) contains information transcribed from the cell's instruction manual, its DNA. The best known of these RNAs translate sections of DNA code into building blocks for proteins.
Most studies of how animals' cells respond to virus infection typically look at protein-coding ...
Montreal −If you are a person who already has stable heart disease, how fast your heart beats at rest can predict your risk of dying, not only from heart disease but all other causes, Dr. Eva Lonn told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
"The higher the heart rate, the higher the risk of death from cardiovascular and all causes, even after adjusting for all risk factors that could confound our results," says Dr. Lonn, a cardiologist and professor at McMaster University. ...
Older adults who survived severe sepsis were more likely to develop substantial cognitive impairment and functional disability, according to a study in the October 27 issue of JAMA.
Hundreds of thousands of patients endure severe sepsis each year in the United States, according to background information in the article. "Although severe sepsis is the most common non-cardiac cause of critical illness, the long-term impact of severe sepsis on cognitive and physical functioning is unknown," the authors write.
Theodore J. Iwashyna, M.D., Ph.D., of the University of Michigan ...
Ann Arbor, Mich. — Older adults who survive severe sepsis are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons, according to researchers from the University of Michigan Health System.
Research to be published Oct. 27 in the Journal of the American Medical Association showed that 60 percent of hospitalizations for severe sepsis were associated with worsened cognitive and physical function among surviving older adults. The odds of acquiring moderate to severe cognitive impairment were 3.3 times higher ...
Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.
"Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors ...
Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online October 9 by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles appear in the October 27 print issue of JAMA.
According to background information in the papers, obesity is among the most significant ...
An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.
Clopidogrel, one of the most commonly prescribed medications, has been shown to reduce cardiovascular events in patients undergoing percutaneous coronary intervention ...
Journals need to develop policies to handle the inevitable competing interests that arise when they publish papers that may bring them reprint revenue or increase their impact factors. This is the conclusion of a research article by Andreas Lundh and colleagues from the Nordic Cochrane Centre published in this weeks PLoS Medicine. An accompanying perspective by Harvey Marcovitch, ex-chair of the Committee on Publication Ethics (COPE), and an editorial from the PLoS Medicine Editors discusses this issue further, concluding that journals should apply the same degree of transparency ...
Current WHO pesticide classifications are based on toxicity in rats but basing regulation on human toxicity will make pesticide poisoning less hazardous and prevent hundreds of thousands of deaths globally without compromising agricultural needs. These are the key findings from a study by Andrew Dawson (South Asian Clinical Toxicology Research Collaboration, University of Peradeniya, Sri Lanka) and colleagues published in this week's PLoS Medicine.
The single most common means of suicide worldwide is agricultural pesticide poisoning. The authors examined the proportion ...
Nagoya, Japan, Wednesday 27 October 2010 (IUCN) – The most comprehensive assessment of the world's vertebrates confirms an extinction crisis with one-fifth of species threatened. However, the situation would be worse were it not for current global conservation efforts, according to a study launched today at the 10th Conference of the Parties to the Convention on Biological Diversity, CBD, in Nagoya, Japan.
The study, to be published in the international journal Science, used data for 25,000 species from The IUCN Red List of Threatened Species™, to investigate the status ...
